Sodium Bicarbonate
drugOn this page
Also known as B1654Baking sodaBicarbonate of sodaCarbonic acid monosodium saltCarbonic acid sodium salt (1:1)E-500(II)Genitron tp-bch 51051Hydrocerol esc 5671INS NO.500(II)INS-500(II)Monosodium carbonateNabicNatrii hydrogenocarbonasNatrum bicarbonicumNSC-134031Nurse harveysS-bicarbS-bicarb sfSodibicSodium acid carbonate
Summary
Sodium Bicarbonate (CHEMBL1353) is an approved small-molecule antacid (ATC B05XA02); indicated across 31 conditions including gastroesophageal reflux disease and kidney disorder.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: B05XA02 (+1 more)
- Indications: 31 conditions
- Clinical trials: 143
- Chemistry: 84.007 Da · CHNaO3
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1353 |
| Name | Sodium Bicarbonate |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | yes |
| PubChem CID | 516892 |
| ChEBI | CHEBI:32139 |
| ATC | B05XA02, B05CB04 |
| Molecular formula | CHNaO3 |
| Molecular weight | 84.007 |
| InChIKey | UIIMBOGNXHQVGW-UHFFFAOYSA-M |
SMILES: C(=O)(O)[O-].[Na+]
IUPAC name: sodium hydrogen carbonate
Pharmacological roles (ChEBI): antacid.
Other ChEBI roles (chemical / environmental): food anticaking agent.
Also known as: B1654, Baking soda, Bicarbonate of soda, Carbonic acid monosodium salt, Carbonic acid sodium salt (1:1), E-500(II), Genitron tp-bch 51051, Hydrocerol esc 5671, INS NO.500(II), INS-500(II), Monosodium carbonate, Nabic
Patent coverage: 451,795 distinct patent families (1,133,637 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 1,002,426 (88%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
31 indications (5 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| gastroesophageal reflux disease | 4 | MONDO:0007186 | EFO:0003948 |
| kidney disorder | 3 | MONDO:0005240 | EFO:0003086 |
| chronic kidney disease | 3 | MONDO:0005300 | EFO:0003884 |
| acute kidney injury | 3 | MONDO:0002492 | HP:0001919 |
| pulpitis | 3 | MONDO:0006937 | EFO:1001139 |
| oropharynx cancer | 3 | MONDO:0004608 | EFO:1001931 |
| constipation disorder | 3 | MONDO:0002203 | HP:0002019 |
| kidney failure | 3 | MONDO:0001106 | EFO:1002048 |
| severe acute respiratory syndrome | 3 | MONDO:0005091 | MONDO:0100096 |
| pharynx cancer | 3 | MONDO:0005517 | EFO:0005577 |
| heart disorder | 2 | MONDO:0005267 | EFO:0003777 |
| dysplasia of cervix | 2 | MONDO:0006736 | EFO:1000910 |
| hematologic disorder | 2 | MONDO:0005570 | HP:0001871 |
| neoplasm | 2 | MONDO:0005070 | MONDO:0004992 |
| injury | 1 | MONDO:0021178 | EFO:0000546 |
| HIV infectious disease | 1 | MONDO:0005109 | EFO:0000764 |
| exocrine pancreatic carcinoma | 1 | MONDO:0005192 | EFO:0002618 |
| cystic fibrosis | 1 | MONDO:0009061 | MONDO:0009061 |
| obesity disorder | 1 | MONDO:0011122 | EFO:0001073 |
| brain edema | 0 | MONDO:0006684 | EFO:1000845 |
| pneumonia | 0 | MONDO:0005249 | EFO:0003106 |
| gastric neoplasm | 0 | MONDO:0021085 | MONDO:0001056 |
| nephrolithiasis | 0 | MONDO:0008171 | EFO:0004253 |
8 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 143.
Phase distribution
| Phase | Trials |
|---|---|
| Not specified | 54 |
| PHASE4 | 27 |
| PHASE3 | 16 |
| PHASE2 | 16 |
| PHASE1 | 15 |
| PHASE2/PHASE3 | 8 |
| EARLY_PHASE1 | 5 |
| PHASE1/PHASE2 | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT05005793 | PHASE4 | RECRUITING | Effect of Alkali Therapy on Vascular and Graft Function in Kidney Transplant Recipients |
| NCT05564130 | PHASE4 | ACTIVE_NOT_RECRUITING | Bicarbonate for In-Hospital Cardiac Arrest |
| NCT07424625 | PHASE4 | NOT_YET_RECRUITING | A Study of Tris-Hydroxymethyl Aminomethane (THAM) Versus Sodium Bicarbonate in Cardiac Surgical Patients |
| NCT07464431 | PHASE4 | NOT_YET_RECRUITING | Sodium Bicarbonate for Critically Ill Patients With Metabolic Acidosis and Acute Kidney Injury |
| NCT00584350 | PHASE4 | UNKNOWN | Prevention of Contrast Nephropathy During Diagnostic Coronary Angiogram or PCI With Hydratation Based on LEVDP |
| NCT00606827 | PHASE4 | COMPLETED | Sodium Bicarbonate Versus Saline for the Prevention of Contrast-induced Nephropathy |
| NCT00639912 | PHASE4 | COMPLETED | Effects of Hydration to Prevent Contrast Induced Nephropathy in PCI for ST-elevation Myocardial Infarction. |
| NCT00693225 | PHASE4 | COMPLETED | Impact of Timing on the Efficacy of Zegerid 40 mg in Healing Reflux Esophagitis: A Pilot Study |
| NCT00700375 | PHASE4 | COMPLETED | Prevention of Contrast-Induced Nephropathy With Sodium Bicarbonate Bolus Injection |
| NCT00950079 | PHASE4 | UNKNOWN | Prevention of Contrast-Induced Nephropathy in Diabetic Patients With Undergoing Coronary Angiography |
| NCT01093131 | PHASE4 | WITHDRAWN | Oral Versus Intravenous Hydration to Prevent Contrast Induced Nephropathy |
| NCT01377337 | PHASE4 | UNKNOWN | Sodium Bicarbonate in Cardiopulmonary Resuscitation |
| NCT01622296 | PHASE4 | COMPLETED | Comparison of Pain of Conventional to Buffered Local Anesthesia During Injection in Pediatric Dental Patients |
| NCT01920126 | PHASE4 | COMPLETED | The Effect of Sodium Bicarbonate on Postoperative Renal Function in Infective Endocarditis Patients Undergoing Open Heart Surgery |
| NCT01962493 | PHASE4 | COMPLETED | An Efficacy Study of Stain Control of a 67% Sodium Bicarbonate Containing Toothpaste on Chlorhexidine Tooth Staining |
| NCT02502071 | PHASE4 | COMPLETED | Effect of Urinary Alkalinization on Urine Uric Acid Precipitation and Crystallization in Adults With Type 1 Diabetes |
| NCT02627846 | PHASE4 | COMPLETED | Laser Ablation Versus Mechanochemical Ablation Trial |
| NCT02647892 | PHASE4 | TERMINATED | Optimal Lidocaine Buffering to Reduce Injection Pain in Local Anesthesia |
| NCT02761577 | PHASE4 | COMPLETED | A Prospective Study on Incidence and Prevention of Contrast-induced Nephropathy in Croatia |
| NCT03121053 | PHASE4 | UNKNOWN | Preventing contrAst Induced Nephropathy After TranscathEter Aortic Valve Replacement |
| NCT04054128 | PHASE4 | UNKNOWN | Bicarbonate vs Heparin Catheter Lock in Chronic Hemodialysis Patients |
| NCT04095975 | PHASE4 | COMPLETED | Effectiveness of Urinary Alkalinizing Agents on Kidney Stone Risk |
| NCT04530448 | PHASE4 | TERMINATED | Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization |
| NCT04773236 | PHASE4 | UNKNOWN | Evaluation of Buffered Local Anesthesia in Dental Extraction. |
| NCT05818007 | PHASE4 | COMPLETED | Is Hyaluronic Acid Gel Effective on Oral Mucositis in Children Who Receiving Chemotherapy |
| NCT06047366 | PHASE4 | TERMINATED | Combination of Buffered Anesthetic to Treat Mandibular Molars |
| NCT06367452 | PHASE4 | COMPLETED | Exploratory Pilot Study to Evaluate the Pharmacokinetic Profile of Magaldrate |
| NCT05697770 | PHASE3 | ACTIVE_NOT_RECRUITING | SODium BICarbonate for Metabolic Acidosis in the ICU |
| NCT05719467 | PHASE3 | RECRUITING | SAINT: Safe Induction of Labor Trial |
| NCT06999993 | PHASE2/PHASE3 | ACTIVE_NOT_RECRUITING | Efficacy and Safety of Sodium Hyaluronate Gel Combined With Sodium Bicarbonate Versus Sodium Bicarbonate Alone in Prevention of Failed Back Surgery Syndrome |
| NCT07231900 | PHASE2/PHASE3 | NOT_YET_RECRUITING | Sodium Bicarbonate in Intra-dialytic Hypertension in Chronic Hemodialysis Patients |
| NCT00312117 | PHASE3 | COMPLETED | Trial for Prevention of Contrast Nephropathy With Sodium Bicarbonate |
| NCT00424320 | PHASE3 | UNKNOWN | Clinical Trial of Sodium Bicarbonate to Prevent Contrast-Induced Nephropathy |
| NCT00497328 | PHASE2/PHASE3 | COMPLETED | COmbined N-acetylcysteine and Bicarbonate in PCI To Reduce Adverse Side Effect of contrasT |
| NCT00522756 | PHASE3 | UNKNOWN | Preventing Acute Renal Failure After Cardiac Surgery in High Risk Patients Using Sodium Bicarbonate Therapy |
| NCT00672334 | PHASE2/PHASE3 | TERMINATED | Sodium Bicarbonate in Cardiac Surgery Study |
| NCT00674115 | PHASE3 | COMPLETED | A Pharmacodynamic Study Comparing Zegerid® and Prilosec OTC® (CL2007-17 )(P07813)(COMPLETED) |
| NCT00765206 | PHASE3 | COMPLETED | A Pharmacodynamic Study Comparing Zegerid® and Prilosec OTC® (Study CL2008-02)(P07814)(COMPLETED) |
| NCT00888290 | PHASE2/PHASE3 | COMPLETED | Sodium Bicarbonate Supplementation in Chronic Kidney Disease Evaluation of Dose Response, Safety and Beneficial Effects |
| NCT00930436 | PHASE3 | TERMINATED | Evaluation of Sodium Bicarbonate to Reduce the Incidence of Contrast Induced Chronic Kidney Injury in Patients With Kidney Disease |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).